$162.18−0.60 (−0.37%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Repligen (RGEN) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~2.4%/yr (FY21→FY25), net margin 6.6%, and free cash flow (~$93.9M) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($M)▲16.4%
738.3
FY21→FY25CAGR +2.4%/yr
Net income ($M)—
48.9
one-off year: see footnoteCAGR −21.4%/yr
Free cash flow ($M)▼37.3%
93.9
FY21→FY25CAGR +16.0%/yr
Diluted EPS—
0.86
FY21→FY25CAGR −21.3%/yr
What the receipts whisper · what a headline number hides
Share count
−1.2%
57.3mn → 56.6mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$23.5M
steady at 3.2% of revenue (−8.4% YoY).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
7¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 58.3% → 52.3%. Net margin 6.6% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 805.6 | 738.3 | 634.4 | 632.4 | 801.5 | 670.5 | ▲16.4% | +2.4% |
Cost of revenue | 374.9 | 352.0 | 359.8 | 353.9 | 345.8 | 279.3 | ▼2.2% | +6.0% |
Gross profit | 430.7 | 386.2 | 274.6 | 278.4 | 455.7 | 391.3 | ▲40.6% | −0.3% |
Research & development | 57.2 | 54.2 | 43.2 | 42.7 | 43.9 | 34.3 | ▲25.4% | +12.1% |
Selling, general & admin | 312.0 | 290.5 | 263.4 | 218.6 | 215.8 | 183.9 | ▲10.3% | +12.1% |
Total operating expenses | 412.4 | 331.1 | 309.8 | 230.7 | 231.0 | 224.0 | ▲6.9% | +10.3% |
Operating incomefeeds ROC rank | 18.2 | 55.2 | −35.1 | 47.7 | 224.7 | 167.2 | — | −24.2% |
Other income, net | −10.0 | 7.2 | 8.1 | 9.0 | −5.5 | −13.7 | — | — |
Pretax income | 8.2 | 62.4 | −27.0 | 56.7 | 219.1 | 153.5 | — | −20.2% |
Income tax | 20.0 | 13.5 | −1.5 | 21.1 | 33.2 | 25.3 | — | −14.5% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | −11.8 | 48.9 | −25.5 | 35.6 | 186.0 | 128.3 | — | −21.4% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.20 | 0.86 | −0.46 | 0.63 | 3.24 | 2.24 | — | −21.3% |
Diluted shares (mn) | 56.56 | 56.56 | 55.94 | 56.38 | 57.45 | 57.26 | ▲1.1% | −0.3% |
| Margins | ||||||||
Gross margin33rd pct in Healthcare | 53.5% | 52.3% | 43.3% | 44.0% | 56.9% | 58.3% | ▲9.0pp | −6.0pp |
Operating margin | 2.3% | 7.5% | −5.5% | 7.5% | 28.0% | 24.9% | ▲13.0pp | −17.5pp |
Net margin37th pct in Healthcare | −1.5% | 6.6% | −4.0% | 5.6% | 23.2% | 19.1% | ▲10.6pp | −12.5pp |
† TTM = trailing four quarters through 2026-09-30.FY23 effective tax rate was 37% vs a 16% norm for this window, likely a one-time item; see the filing.FY24 effective tax rate was 6% vs a 16% norm for this window, likely a one-time item; see the filing.
5 more years of statements and CSV export are on Premium, and 11 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Repligen's revenue last fiscal year?
Repligen reported revenue of $738.3M in fiscal 2025, up 16.4% from fiscal 2024.
What was Repligen's net income?
Repligen reported net income of $48.9M in fiscal 2025, a net margin of 6.6%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

